Every year, IDWeek™ provides a forum for leading researchers, healthcare professionals and infectious disease experts from around the world to come together to exchange ideas and share the latest advancements across infectious diseases, including progress in both the treatment and prevention of HIV.
In 2023, we’re eager to share new findings from across our HIV treatment and prevention portfolio that put the voice of the community at the center and reaffirm our commitment to leaving no person with HIV behind.
- Our key data include real-world evidence findings that provide a more comprehensive picture of how different therapeutic approaches can best meet the needs of the HIV community.
- We’ll also share patient preference results that further our understanding of key elements of care beyond viral suppression and underscore the importance of developing diverse and innovative treatment and prevention options to address individual needs.
- Additional presentations include findings from national surveys asking women about PrEP perceptions and uptake to inform awareness and usage.
- As a part of our commitment to leaving no person with HIV behind, we’ll share long-term trial results across patient populations with specific treatment considerations including those with multi-drug resistant HIV and those aging with HIV.
Title |
First Author |
Presentation Type |
|---|---|---|
| Dolutegravir | ||
| Virological suppression in people with HIV-1 (PWH) receiving dolutegravir/lamivudine was high and similar across age groups despite older PWH having increased rates of comorbidities and polypharmacy (TANDEM subgroup analysis) (encore) |
A. Brogan |
Poster |
| Cabotegravir for HIV Treatment | ||
| Real-world adherence and persistence with long-acting cabotegravir plus rilpivirine (CAB+RPV LA) compared to oral antiretroviral therapy (ART) among people with HIV (PWH) in the US: the ABOVE study | C. Garris | Oral |
| Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND) | G. Sinclair | Poster |
| Perspectives of people with HIV (PWH) 6 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) | D. Dandachi | Poster |
| SOLAR 12-month North American results: randomized switch trial of CAB+RPV LA vs. oral BIC/FTC/TAF | J. M. McKellar | Poster |
| Real-world effectiveness of long-acting cabotegravir + rilpivirine in virologically suppressed treatment-experienced individuals: two years of data from the OPERA cohort | M. Sension | Poster |
| Real-world use of long-acting cabotegravir + rilpivirine in people with HIV with detectable viral loads at initiation: findings from the OPERA cohort | R. Hsu | Oral |
| Real-world utilization and effectiveness of long-acting cabotegravir + rilpivirine among people with HIV with detectable viral loads at initiation: TRIO cohort study | R. Ellon | Poster |
| Cabotegravir for HIV PrEP | ||
| Healthcare staff perceptions of feasibility and acceptability on implementing injectable HIV pre-exposure prophylaxis into standard of care: baseline results from the PrEP Implementation Study for cabotegravir long acting for men in the real world (PILLAR) | J. Torres | Poster |
| Engaging Black women on cabotegravir LA for PrEP by optimizing novel implementation strategies (EBONI) study: provider perceptions of appropriateness of cabotegravir LA for PrEP for cis- and-trans Black women | T. Richmond | Poster |
| Integrating long-acting injectable cabotegravir for PrEP into standard of care for cisgender women, transgender women, transgender men, and men who have sex with men: results from the PILLAR & EBONI studies | W. Valenti | Poster |
| HIV acquisition following oral pre-exposure prophylaxis (PrEP) initiation | A. Metzner | Poster |
| Acceptability of an HIV pre-exposure prophylaxis (PrEP) shared decision-making tool for diverse populations and healthcare providers | W. Davis | Poster |
| Exploring cisgender women’s HIV pre-exposure prophylaxis (PrEP) needs and preferences across settings | D. Kerrigan | Poster |
| Risk factors, risk perception, and long-acting PrEP awareness and interest among US women: a national survey | T. Poteat | Poster |
| Fostemsavir | ||
| Durable efficacy and robust CD4+ T-cell count improvement observed among age, race, sex, and geographic subgroups of heavily treatment-experienced people with multidrug-resistant HIV-1 after 240 weeks of fostemsavir treatment | A. Dyson | Poster |
ViiV Healthcare Events at IDWeek™ 2023
Explore our Learning Lounge Events throughout the congress
In addition to our scientific data presented at IDWeek™ 2023, ViiV Healthcare is excited to host one Satellite Symposium and three Learning Lounges, covering timely topics in HIV treatment and prevention.
Title |
Date |
Time |
|---|---|---|
| Satellite Symposium HIV Management: Clinical Case Conundrums – A Wheel Of Knowledge Challenge! |
October 12 | 7 – 9 PM ET |
| Learning Lounge Patient And Physician Conversations: An Overview Of Clinical Data For A Long-acting HIV Treatment And A Patient Ambassador’s Perspective |
October 13 | 11:15 AM – 12 PM ET |
| Learning Lounge PrEP Today. Data Discussions On An HIV-1 PrEP Option |
October 13 | 12:15 – 1 PM ET |
| Learning Lounge Real World Evidence In HIV Treatment |
October 13 | 1:15 – 2 PM ET |
OUR STORIES: SCIENCE AND INNOVATION
To lift the substantial burdens of daily treatment and social stigma associated with HIV, a cure is essential to accomplishing our goal of ending the HIV epidemic. With this goal in mind, we are in pursuit of a cure for HIV.
Collaboration is the key to finding solutions to HIV challenges – and it’s at the heart of what we do at our HIV research facility in Branford, Connecticut.
Women make up more than half of all people living with HIV – why are they under-represented in studies of new medicines?
